...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Long-term Safety of Testosterone and Growth Hormone Supplementation: A Retrospective Study of Metabolic, Cardiovascular, and Oncologic Outcomes
【24h】

Long-term Safety of Testosterone and Growth Hormone Supplementation: A Retrospective Study of Metabolic, Cardiovascular, and Oncologic Outcomes

机译：睾丸激素和生长激素补充剂的长期安全性：代谢，心血管和肿瘤结果的回顾性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Clinical research into the effects of hormonal supplementation has tended to focus on beneficial changes in anthropometric measures. There are fewer data on long-term safety with extended hormonal supplementation.Methods: As part of a retrospective database survey, clinical outcomes were tabulated among patients who received at least 1 year of testosterone and/or growth hormone (GH) supplementation. In patients who were treated for at least 2 years, changes in markers of glucose and lipid metabolism were analyzed with and without concomitant use of oral hypoglycemics and statins.Results: In 263 patients (mean age 56) treated for at least 2 years, the only statistically significant effect on markers of glucose metabolism was an increase in glycated hemoglobin (still within normal limits) in patients receiving GH alone or in combination with testosterone but without oral hypoglycemics; with or without hypoglycemics, insulin levels showed no significant change. The only significant effects on markers of lipid metabolism were decreases in total cholesterol and low-density lipoprotein (LDL) in patients receiving combined testosterone and GH without statins. Decreases in LDL were significant in both the statin and non-statin groups; decreases in triglycerides were significant only in the statin group. In 531 patients treated for at least 1 year (mean age 54), the overall incidence of adverse clinical outcomes (prostate disease, diabetes, cardiovascular disease, cancer) was 1.3%.Conclusions: In this retrospective survey, extended testosterone and/or GH supplementation did not adversely affect metabolic markers or clinical outcomes.doi:10.4021/jocmr428w
机译：背景：关于激素补充作用的临床研究倾向于集中在人体测量学方法的有益变化上。方法：作为一项回顾性数据库调查的一部分，对接受了至少一年睾酮和/或生长激素（GH）补充的患者的临床结局进行了制表，这是一项回顾性数据库调查的一部分。在接受至少2年治疗的患者中，分析了是否使用口服降糖药和他汀类药物时血糖和脂质代谢指标的变化。结果：治疗至少2年的263名患者（平均年龄56岁）仅对单独或与睾丸激素联合使用但未口服降糖药的GH患者，对葡萄糖代谢指标的统计学显着影响是糖化血红蛋白增加（仍在正常范围内）;无论有无降糖，胰岛素水平均无明显变化。接受睾丸激素和GH联合他汀类药物治疗的患者，对脂质代谢标志物的唯一显着影响是总胆固醇和低密度脂蛋白（LDL）降低。他汀类药物和非他汀类药物组的低密度脂蛋白下降均显着;甘油三酯的减少仅在他汀类药物组中显着。在531位至少接受1年治疗（平均年龄54岁）的患者中，不良临床结局（前列腺疾病，糖尿病，心血管疾病，癌症）的总发生率为1.3％。结论：在这项回顾性调查中，扩大了睾丸激素和/或GH补充对代谢指标或临床结果没有不利影响。doi：10.4021 / jocmr428w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号